Wycena firm — Healthcare Devices

Uwaga: szczegóły branżowe i FAQ poniżej są w języku angielskim. Przejdź do pełnej wersji angielskiej →

Dla kogo jest ta wycena

Medical device founders seeking strategic acquisition or growth equity, large medtech corporate development teams benchmarking bolt-on targets, and medtech venture investors marking positions to market.

Co napędza wartość w branży Healthcare Devices

  • FDA clearance or approval status (510(k), PMA, De Novo) and IP protection
  • Recurring revenue from disposables, service contracts, or software subscriptions
  • Clinical evidence depth and published outcomes data
  • Commercial traction: procedure volumes, installed base, and ASP trends
  • Sales force infrastructure and GPO/IDN contract coverage
  • Pipeline of next-generation products leveraging cleared platform

Metody wycen, które stosujemy

Commercial-stage medical device companies are valued on revenue multiples (3–8×) and EBITDA multiples (15–25× for high-growth devices). Pre-commercial devices are valued on pipeline-adjusted comparable transaction analysis. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.

Zastrzeżenie: Value Alpha to narzędzie do estymacji oparte na AI. Wszystkie wyniki są wyłącznie informacyjne i w pełni wynikają z Twoich danych wejściowych. To nie jest formalna wycena, certyfikowany operat szacunkowy ani porada inwestycyjna. Dla formalnej wyceny skorzystaj z usług uprawnionego rzeczoznawcy.

Typowe metryki i dane wejściowe

Recurring revenue %

Share of revenue from disposables, service, or SaaS; recurring revenue commands higher multiples than capital equipment.

ASP trend

Average selling price trajectory; rising ASP signals commercial execution and value capture.

Procedure volume growth

Year-over-year growth in procedures using the device; the leading commercial adoption indicator.

Gross margin

Typically 55–75% for medical devices; higher for software-embedded or disposable-heavy models.

Revenue growth rate

Annual revenue growth; 20–50%+ YoY is expected for premium multiples in medtech.

Przykładowe scenariusze

FDA-cleared minimally invasive surgical device

A surgical device company with $10 M revenue growing 40%, 65% gross margin, and expanding procedure adoption might be valued at 5–7× revenue by a strategic acquirer.

Software-embedded diagnostic device

A diagnostic device with embedded AI software, $3 M ARR from SaaS subscriptions, and 510(k) clearance might trade at 8–12× revenue.

Często zadawane pytania

What multiple does a medical device company sell for?

Commercial-stage devices with strong growth: 4–8× revenue. Profitable medtech platforms: 15–25× EBITDA. Strategic premiums can push these higher for category-defining products.

How much does FDA clearance add to value?

Significant - FDA clearance de-risks the clinical and regulatory path, unlocking commercial adoption. A cleared device is typically valued at 5–10× the value of a pre-cleared device in the same category.

Why does recurring revenue matter for medical devices?

Disposable or software-linked revenue extends customer LTV, reduces revenue volatility, and supports SaaS-like valuation multiples rather than one-time capital equipment multiples.

What do large medtech companies look for in acquisitions?

Technology platform adjacency, strong clinical evidence, GPO/IDN access, and a commercial team that can accelerate with the acquirer's distribution network.

Is this a certified appraisal?

No. This tool provides informational estimates. For formal medtech M&A, engage a healthcare-focused investment banker.

Uruchom swoją wycenę — Healthcare Devices

Otrzymaj profesjonalny raport wyceny oparty na DCF, spółkach porównywalnych, transakcjach precedensowych i analizie scenariuszy — za jedyne 199 USD.